{
    "Trade/Device Name(s)": [
        "Lyphochek Whole Blood Immunosuppressant Control",
        "Abbott Immunosuppressant MCC"
    ],
    "Submitter Information": "Bio-Rad Laboratories",
    "510(k) Number": "K072721",
    "Predicate Device Reference 510(k) Number(s)": [
        "K022041"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "DIF"
    ],
    "Summary Letter Date": "September 21, 2007",
    "Summary Letter Received Date": "September 26, 2007",
    "Submission Date": "September 13, 2007",
    "Regulation Number(s)": [
        "21 CFR 862.3280"
    ],
    "Regulation Name(s)": [
        "Clinical Toxicology Control Material"
    ],
    "Analyte Class(es)": [
        "toxicology",
        "tdm"
    ],
    "Analyte(s)": [
        "Sirolimus",
        "Tacrolimus",
        "Cyclosporine"
    ],
    "Specimen Type(s)": [
        "Whole Blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Lyphochek Whole Blood Immunosuppressant Control and Abbott Immunosuppressant MCC as assayed quality control materials for immunosuppressant drugs in whole blood",
    "Indications for Use Summary": "Intended for use as assayed quality control material to monitor the precision of laboratory testing procedures for sirolimus, tacrolimus, and cyclosporine in whole blood",
    "fda_folder": "Toxicology"
}